Colon cancer is a major global health concern and is one of the leading causes of cancer related deaths. Therefore, its early detection and subtyping is crucial for improving patient outcomes. This can be made possible by using multi-omics datasets which allows to consider molecular structure in diagnosis. However, their high-dimensional, nonlinear, and sample-limited datasets pose significant difficulties for purely classical machine learning models. This work proposes a hybrid quantum-classical framework for stage-wise colon cancer detection & consensus molecular subtype (CMS) subtyping using curated omics datasets and a three-stage conditional pipeline to overcome these limitations. The suggested methodology allows for excellent feature compression by amplitude encoding while capturing intricate nonlinear interactions, making it especially useful for small-sample, high-dimensional biological information. To make it interpretable, Q-SHAP is employed which helps in biomarker discovery and makes the model clinician friendly.
Colon cancer is a major global health concern and is one of the leading causes of cancer related deaths. Therefore, its early detection and subtyping is crucial for improving patient outcomes. This can be made possible by using multi-omics datasets which allows to consider molecular structure in diagnosis. However, their high-dimensional, nonlinear, and sample-limited datasets pose significant difficulties for purely classical machine learning models. This work proposes a hybrid quantum-classical framework for stage-wise colon cancer detection & consensus molecular subtype (CMS) subtyping using curated omics datasets and a three-stage conditional pipeline to overcome these limitations. The suggested methodology allows for excellent feature compression by amplitude encoding while capturing intricate nonlinear interactions, making it especially useful for small-sample, high-dimensional biological information. To make it interpretable, Q-SHAP is employed which helps in biomarker discovery and makes the model clinician friendly.
Quantum machine learning (QML) presents novel opportunities for resolving, accelerating, and refining computational biology challenges. In biomedical research and personalized medicine, multi-omics integration offers a comprehensive understanding of complex biological systems, bridging the gap between basic research and clinical applications. Recent advancements in quantum computing could enhance multi-omics integration by leveraging unique quantum principles, potentially revealing intricate patterns in multi-omics datasets and offering new insights into the molecular landscape of lung cancer. This study focuses on the integration, feature selection, diagnostic classification, and biomarker identification of lung cancer types-LUAD primary tumor and solid tissue normal-using QML. Given the heterogeneity and high dimensionality of the data, we aim to assess the performance of QML in feature selection, reduction, encoding, and diagnostic classification in integrated multi-omics cancer datasets. We demonstrate the efficacy of Quantum Neural Networks (QNNs) for classifying multi-omics lung cancer data from The Cancer Genome Atlas, comparing our framework with 16 and 64 dimensions of feature using QML. Our results show that the Multi-omic Quantum Machine Learning (MQML) framework achieves superior classification performance with smaller training datasets, as determined by significant and non-significant p-values. This study provides empirical evidence for the potential application of unconventional computing approaches in biomed-ical sciences, particularly in oncology research, including cancer subtype diagnostic, survival, and stage classification. Key results include the identification of sixteen genes and thirty-two genes with the hybrid quantum-classical neural net-work model, with notable genes such as MIR632, CYP19A1, RP11-108K3.1, C14orf39, THUMPD1, ACSM3, GSC, MIR92a-2, DYRK1B, DNAJA1, IRX1, FMR1, POU2F2, MIR9-2, ZNF274, MIR196a-1, MIR3653, MIR33b, MIR301a, MIR182, MIR520a, PYGO2, EMX2OS, EMX2, RP11-550F7.1, RPS11, MIR20a, EIF4G2, IGLV1-47, RP11-180M15.7, SCYL3, AC107081.5, C2orf47, FST, MIR7-1, SLC22A18, CLDN5, and AC007879.7 identified as having significant and non-significant p-values asso-ciated with LUAD patient predictions.
Subtyping of lung cancer is crucial for individualized treatment and optimizing outcomes. Computational modeling allows data analysis over large scales, which helps in making precision classification in large datasets or high-dimensional datasets. Conventional machine learning methods perform well, but integration of multi-omic data (DNA, RNA, miRNA) is challenging in cancer subtyping because of high dimensionality and complex inter-omic relationships. To bypass this Quantum machine learning (QML) provides better ability to navigate high-dimensional biological data with many variables using quantum computational concepts that can identify fine patterns or small-scale patterns beyond the capability of classical approaches. Through the integration of quantum computing principles with the machine learning framework, the study highlights the improvement of computer technology. The framework shows how the system is optimized with the help of quantum principles, how it can improve accuracy, parallel processing and reducing latency. In this work, we have combined data on miRNA, RNA expression, and DNA methylation to create a complete workflow for classifying cancer. This method uses a wide variety of feature selection techniques, such as random forest-based selection, chi-square, mutual information(MI), and principal component analysis(PCA).In order to illustrate the notion of quantum advantage, we carefully compare the performance metrics of the Quantum Support Vector Classifier (QSVC) to the classical Support Vector Machine (SVM), using a ZZ feature map quantum kernel as our baseline for analysis. Using five-fold crossvalidation, we have also verified that the quantum has an advantage with consistently lower variance and higher accuracy.
Chronic diseases—such as diabetes, cardiovascular disorders, and chronic respiratory conditions—account for over 70% of global deaths annually, with late diagnosis being a primary contributor to poor outcomes. While machine learning (ML) models have shown promise in early detection, they often suffer from limited generalizability, data heterogeneity, and insufficient interpretability in clinical settings. This paper introduces a novel hybrid quantum-classical machine learning (HQML) framework that synergistically combines the pattern recognition power of classical deep neural networks with the high-dimensional optimization capabilities of quantum algorithms to enhance diagnostic accuracy, robustness, and early signal detection in chronic disease prediction. Using multimodal electronic health record (EHR) data—including clinical, genomic, and lifestyle variables—we train a quantum-enhanced feature selector followed by a classical interpretable classifier (e.g., SHAP-augmented XGBoost). The quantum component leverages a variational quantum circuit to identify non-linear, high-order feature interactions that classical methods often miss. Validated on datasets from the National Health and Nutrition Examination Survey (NHANES) and UK Biobank, our model achieves 94.7% AUC for type 2 diabetes prediction five years before clinical diagnosis—outperforming state-of-the-art baselines by 6.2%. Crucially, the framework maintains interpretability through post-hoc explainability and reduces data bias via fairness-aware quantum embedding. This research bridges quantum computing and public health, offering a scalable, ethically grounded diagnostic paradigm. By enabling earlier, more accurate, and equitable predictions, the HQML framework has significant potential to transform preventive care and reduce the global burden of chronic disease.
Multi-omics integration has become a cornerstone of personalized medicine, enabling researchers to connect genomic, transcriptomic, proteomic, metabolomic, and epigenomic data to reveal complex biological mechanisms and individualized disease signatures. However, the extreme dimensionality, heterogeneity, and nonlinear interactions across omics layers challenge even the most advanced classical machine learning methods. Quantum Machine Learning (QML) offers a powerful alternative by exploiting quantum superposition, entanglement, and high-dimensional feature embeddings to model multi-omics interactions more efficiently. This study proposes a hybrid quantum–classical framework that combines quantum kernel estimation, variational quantum classifiers, and quantum-enhanced feature fusion networks to generate integrative biological signatures for precision diagnostics. Simulation results using benchmark multi-omics datasets demonstrate improved classification accuracy, enhanced sensitivity to weak biological signals, and reduced computational overhead compared to classical baselines. These findings highlight the potential of QML to accelerate multi-omics insights and pave the way toward truly personalized, predictive healthcare.
Cancer remains a major global health challenge, necessitating the development of accurate, scalable, and clinically reliable diagnostic approaches. Artificial intelligence (AI) has significantly enhanced cancer detection through advanced analysis of medical imaging, histopathology, and multi-omics data. However, conventional AI models face limitations related to computational scalability, optimization complexity, and data heterogeneity. Quantum computing introduces a fundamentally different computational paradigm based on superposition, entanglement, and probabilistic state evolution. The integration of quantum computing with machine learning referred to as Quantum Artificial Intelligence (QAI) has emerged as a promising approach to address these challenges. This review critically evaluates the role of QAI in cancer detection through a systematic analysis of literature published between 2015 and 2026. The findings suggest that QAI can enhance feature representation, accelerate optimization processes, and improve predictive performance. Hybrid quantum-classical models show potential in tumor classification, multi-omics integration, and real-time clinical decision-making. Despite these advances, significant challenges remain, including hardware limitations, lack of large-scale validation, and ethical concerns. Overall, QAI represents a promising yet emerging paradigm with potential to transform early cancer detection and precision oncology. This review uniquely synthesizes quantum-AI approaches in oncology, emphasizing hybrid quantum-classical models as the most practical translational pathway for clinical adoption.
Brain tumor classification remains a challenging task due to the complex heterogeneity of glioma characteristics and the limitations of conventional machine learning approaches in effectively integrating multimodal biomedical data. Recent advances in quantum machine learning have demonstrated promising capabilities for handling high-dimensional data; however, existing models often suffer from limited feature representation, insufficient multimodal integration, and optimization challenges. This paper proposes an Enhanced Hybrid Quantum–Classical Architecture (EHQCA) for glioma classification by combining MRI imaging features and TCGA molecular biomarkers within a unified learning framework. The proposed methodology employs ResNet-50 for imaging feature extraction, ensemble feature selection for molecular biomarkers, attention-based multimodal fusion, adaptive amplitude encoding, and a Multi-Layer Variational Quantum Classifier (ML-VQC). A hybrid Adam-SPSA optimization strategy is introduced to improve convergence speed and training stability. Experimental analysis demonstrates that the proposed EHQCA framework achieves superior classification performance, attaining 91.2% accuracy while reducing training epochs compared with existing quantum and classical models. The results highlight the effectiveness of multimodal fusion and quantum-enhanced learning for improving brain tumor diagnosis and supporting precision medicine applications